The report highlights that, “TCS is fortifying its capabilities in the med-tech space, and its business transformation capabilities, providing an end-to-end automated, agile, and Intelligent Business 4.0 framework; end-to-end business operations ownership; value-based consulting; and a cross-business CXO-level focus.” It goes on to say “TCS has been recognized for the strategic direction that it brings to its large clinical transformation programs, providing advisory services for regulatory and clinical IT landscape transformation, R&D business capabilities mapping, R&D long-range planning, and portfolio simplification and its expertise in everything related to data.”
“The pandemic has brought unprecedented collaboration and acceleration in life sciences companies’ R&D initiatives. These companies are partnering with TCS to develop the right transformation strategy, innovatively harness next-gen technologies such as AI, IoT and blockchain to accelerate and expand their R&D programs, enhance business outcomes and achieve purpose-led growth,” said Vikram Karakoti, Global Co-Head, Life Sciences, TCS. “This leadership position is a reflection of our strong vision, consulting capabilities, investments in innovation and the resultant market success.”
TCS partners with leading life sciences companies to drive innovation and reimagine their R&D processes by leveraging next generation platforms and emerging technologies.
TCS offers a full set of services spanning advisory, digital transformation, and cognitive business operations in areas such as M&A and divestitures, IT consulting, supply chain management, digitization of clinical trials, paperless and integrated lab environment, blockchain-enabled clinical supply chain, AI-enabled case processing, and discovery collaboration.
The solutions use a combination of artificial intelligence, cognitive computing capabilities, robotic process automation, IoT and cloud to fully digitize the life sciences value chain, the IT company said.